Binding of deferoxamine to asbestos fibers in vitro and in vivo

Our plain-English summary of Binding of deferoxamine to asbestos fibers in vitro and in vivo, by S.A. Weitzman, J.F. Chester, P. Graceffa (Carcinogenesis, 1988).

The study

• Authors: S.A. Weitzman, J.F. Chester, P. Graceffa
• Journal: Carcinogenesis
• Published: 1988;9(9):1643-5
• Cited by: 21 articles, as counted by NIH iCite
• Read it: PubMed · Publisher

Abstract

We studied the binding of tritium-labeled deferoxamine, a strong iron chelator, to crocidolite asbestos fibers in vitro and in vivo. In aqueous suspension of asbestos, deferoxamine binding was rapid and strong, suggesting specific binding to iron. For the in vivo experiments, diffusion chambers containing native asbestos fibers or deferoxamine-washed asbestos were implanted in the peritoneal cavities of mice. Five days after parenteral injection of tritiated deferoxamine chambers were removed and the asbestos counted. More than twice as much label (2206 +/- 348 c.p.m./100 mg asbestos) was bound to the native asbestos as compared to the deferoxamine-washed asbestos (1080 +/- 201 c.p.m./100 mg asbestos), suggesting specific binding in vivo. Since deferoxamine can inhibit asbestos toxicity in vitro, these experiments suggest the feasibility of testing whether deferoxamine can prevent asbestos-related disease in vivo.

In plain English

This laboratory and animal study tested whether deferoxamine, a drug that strongly binds iron, attaches to crocidolite asbestos fibers. In the laboratory, the authors mixed radioactively labeled deferoxamine with crocidolite suspended in water. Binding reached essentially its maximum within 1 minute and stayed stable over 18 hours. The authors wrote that the strong binding suggested specific binding to iron. In the animal part, sealed chambers holding either untreated crocidolite or crocidolite pre-soaked in deferoxamine were placed in the peritoneal (abdominal) cavities of mice. Eleven mice survived the surgery. Each mouse received an intramuscular injection of labeled deferoxamine, and the chambers were removed five days later. Untreated asbestos carried more than twice as much label (2206 ± 348 counts per minute per 100 mg) as pre-soaked asbestos (1080 ± 201). After 6 weeks of storage in water, 20.7% and 22.7% of the initial counts remained. The study measured binding only, not disease. The authors concluded that deferoxamine binds rapidly to asbestos and that some of this binding may be specific. They said testing whether it can prevent asbestos-related disease in animals appeared feasible.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Laboratory (in vitro) binding experiments plus an animal experiment using asbestos-filled diffusion chambers implanted in mice
• Who was studied: Crocidolite asbestos samples in water suspension; for the animal part, 12 diffusion chambers (six with untreated crocidolite, six with deferoxamine-soaked crocidolite) implanted in the peritoneal cavities of mice (strain printed as "CD-I" in the scanned text). One mouse died immediately and 11 survived. No dates are given.
• Exposure: Crocidolite asbestos from the UICC Reference Standard samples, exposed to tritium-labeled deferoxamine. In the mice, each animal received an intramuscular injection of 0.1 mCi tritiated deferoxamine 24 hours after chamber implantation, and chambers were removed five days later.
• Main results:
  • In the laboratory, deferoxamine binding to crocidolite reached essentially its maximum within 1 minute and was stable over the 18-hour incubation period.
  • In competition experiments, unlabeled deferoxamine reduced the amount of labeled deferoxamine bound, but binding was not saturable over the concentrations studied. The authors said the strong binding suggested specific binding to iron.
  • In the mouse diffusion chambers, untreated crocidolite bound more than twice as much label (2206 ± 348 c.p.m. per 100 mg asbestos) as deferoxamine-washed crocidolite (1080 ± 201 c.p.m. per 100 mg asbestos). Values are means with standard errors.
  • After the chamber asbestos was stored in water for 6 weeks, counts were 457 c.p.m. per 100 mg for untreated asbestos and 245 c.p.m. per 100 mg for deferoxamine-washed asbestos. These were 20.7% and 22.7% of the initial counts.
• The authors' conclusion: The authors concluded that deferoxamine rapidly binds to asbestos fibers, that some of this binding may be specific, and that the binding appears fairly stable. They said their experiments suggest it is feasible to test whether deferoxamine can prevent asbestos-related disease in living animals.
• Limitations the authors state:
  • The authors stated that they did not yet know which binding sites are essential for preventing asbestos toxicity.
  • The authors noted that animal studies were still needed to find out whether deferoxamine can prevent asbestos-induced disease. This study did not test disease prevention.

Topics

Medical terms in this study, explained in our Lexicon: Crocidolite.

Related studies

• Sialic acid-binding lectin from bullfrog eggs inhibits human malignant mesothelioma cell growth in vitro and in vivo — T. Tatsuta, T. Satoh, et al. (2018)
• In vitro studies on the biologic effects of fibers: correlation with in vivo bioassays — B.T. Mossman (1990)
• Inhalable particles and pulmonary host defense: in vivo and in vitro effects of ambient air and combustion particles — G.E. Hatch, E. Boykin, et al. (1985)
• Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy — M.A. Hoda, A. Mohamed, et al. (2011)
• Experimental results using 3-bromopyruvate in mesothelioma: in vitro and in vivo studies — P. Icard, X.D. Zhang, et al. (2012)
• Studies on the morphological patterns of asbestos induced mesotheliomas in vivo and in vitro — I.P. Gormley, R.E. Bolton, et al. (1980)

Browse more research in Carcinogenesis, or return to medical research.